John Oyler, BeiGene CEO (Endpoints News, PharmCube)
July 14, 2022 07:03 AM EDTUpdated 07:16 AM
China
Pharma
FDA+

No­var­tis’ $650M cash bet on a near-term FDA OK for BeiGene’s Chi­na PD-1? It just got de­layed in­def­i­nite­ly

Amber Tong

A not-so-fun­ny thing hap­pened to No­var­tis’ high-pro­file bid to take a PD-1 check­point out of Chi­na and get it ap­proved in the US this year …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

FDA says Ozem­pic, We­govy short­age is over

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times